NEW YORK (GenomeWeb News) – Investment bank Cowen & Co. today upgraded PerkinElmer's stock, citing favorable end-market exposure and year-over-year comparisons that could result in mid-single digit revenue growth in 2014.

Analyst Doug Schenkel upgraded the company's stock to Outperform from Market Perform, and increased the price target on its shares to $47 from $35.20.

In afternoon trading on Monday, PerkinElmer's shares on the Nasdaq was up 1 percent to $41.68.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.

Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.

A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.

In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more